| Role of synaptotagmin 13 (SYT13) in promoting breast cancer and signaling pathways. | Role of synaptotagmin 13 (SYT13) in promoting breast cancer and signaling pathways.
Zhang YD, Zhong R, Liu JQ, Sun ZX, Wang T, Liu JT. | 10/25/2023 |
| The highly expressed calcium-insensitive synaptotagmin-11 and synaptotagmin-13 modulate insulin secretion. | The highly expressed calcium-insensitive synaptotagmin-11 and synaptotagmin-13 modulate insulin secretion.
Ofori JK, Karagiannopoulos A, Barghouth M, Nagao M, Andersson ME, Salunkhe VA, Zhang E, Wendt A, Eliasson L., Free PMC Article | 08/20/2022 |
| Synaptotagmin 13 Is Highly Expressed in Estrogen Receptor-Positive Breast Cancer. | Synaptotagmin 13 Is Highly Expressed in Estrogen Receptor-Positive Breast Cancer.
Ichikawa T, Shibata M, Inaishi T, Soeda I, Kanda M, Hayashi M, Takano Y, Takeuchi D, Tsunoda N, Kodera Y, Kikumori T., Free PMC Article | 10/30/2021 |
| Synaptotagmin 13 is neuroprotective across motor neuron diseases. | Synaptotagmin 13 is neuroprotective across motor neuron diseases.
Nizzardo M, Taiana M, Rizzo F, Aguila Benitez J, Nijssen J, Allodi I, Melzi V, Bresolin N, Comi GP, Hedlund E, Corti S., Free PMC Article | 06/12/2021 |
| Identification SYT13 as a novel biomarker in lung adenocarcinoma. | Identification SYT13 as a novel biomarker in lung adenocarcinoma.
Zhang L, Fan B, Zheng Y, Lou Y, Cui Y, Wang K, Zhang T, Tan X. | 05/1/2021 |
| Silencing of synaptotagmin 13 inhibits tumor growth through suppressing proliferation and promoting apoptosis of colorectal cancer cells. | Silencing of synaptotagmin 13 inhibits tumor growth through suppressing proliferation and promoting apoptosis of colorectal cancer cells.
Li Q, Zhang S, Hu M, Xu M, Jiang X., Free PMC Article | 10/10/2020 |
| SYT13 levels were significantly associated with shorter peritoneal recurrence-free survival (PRFS) and overall survival in patients with gastric cancer; positive levels of SYT13 and CEA mRNA demonstrated the highest hazards ratio for peritoneal recurrence | The levels of SYT13 and CEA mRNAs in peritoneal lavages predict the peritoneal recurrence of gastric cancer.
Nakanishi K, Kanda M, Umeda S, Tanaka C, Kobayashi D, Hayashi M, Yamada S, Kodera Y. | 04/18/2020 |
| SYT13 expression in gastric cancer is associated with peritoneal metastases. | Synaptotagmin XIII expression and peritoneal metastasis in gastric cancer.
Kanda M, Shimizu D, Tanaka H, Tanaka C, Kobayashi D, Hayashi M, Takami H, Niwa Y, Yamada S, Fujii T, Sugimoto H, Kodera Y. | 03/9/2019 |
| These studies combine to suggest that SYT13 is a liver tumor suppressor gene and that its function may be mediated through pathways implicated in mesenchymal to epithelial transition | Exogenous expression of synaptotagmin XIII suppresses the neoplastic phenotype of a rat liver tumor cell line through molecular pathways related to mesenchymal to epithelial transition.
Jahn JE, Best DH, Coleman WB. | 01/1/2011 |
| Clinical trial of gene-disease association and gene-environment interaction. (HuGE Navigator) | Personalized smoking cessation: interactions between nicotine dose, dependence and quit-success genotype score.
Rose JE, Behm FM, Drgon T, Johnson C, Uhl GR., Free PMC Article | 06/30/2010 |
| human SYT13 functions as a liver tumor suppressor gene that complements a molecular defect in rat liver tumor cells resulting in a normalized cellular phenotype in vitro and suppression of tumorigenicity in vivo | Re-expression of tumorigenicity after attenuation of human synaptotagmin 13 in a suppressed microcell hybrid cell line.
Jahn JE, Coleman WB. | 01/21/2010 |